Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$10.50 -0.08 (-0.76%)
At close: Nov 10, 2026 · 4:00 PM EST

Monte Rosa Therapeutics (GLUE) Receivables (2024)

Updated

Monte Rosa Therapeutics (GLUE) recorded Receivables of $9.84 million in Q2 2024.

Analysis

Monte Rosa Therapeutics (GLUE) Receivables (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 25.23 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 18.99 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 13.51 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 12.74 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 14.33 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 10.35 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 5.01 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 14.19 Bn
10 Monte Rosa Therapeutics 1.08 Bn 490.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 9.84 Mn
API Access

Monte Rosa Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=GLUE&period=max&api_key=YOUR_API_KEY